Content about Sibutramine

February 15, 2013
FDA seizes tainted product from Florida's Globe All Wellness

U.S. marshals, acting on behalf of the Food and Drug Administration, on Thursday seized tainted products from Globe All Wellness in Hollywood, Fla.

SILVER SPRING, Md. — U.S. marshals, acting on behalf of the Food and Drug Administration, on Thursday seized tainted products from Globe All Wellness in Hollywood, Fla. The products may be unsafe because they contain an undisclosed active pharmaceutical ingredient.

January 8, 2013
FDA advises consumers not to purchase adulterated 'MAXILOSS Weight Advanced'

The Food and Drug Administration on Tuesday advised consumers not to purchase or use “MAXILOSS Weight Advanced” — a product promoted and sold for weight loss on various web sites, including DreamLifeWeightLoss.com, and in some retail stores.

SILVER SPRING, Md. — The Food and Drug Administration on Tuesday advised consumers not to purchase or use “MAXILOSS Weight Advanced” — a product promoted and sold for weight loss on various web sites, including DreamLifeWeightLoss.com, and in some retail stores.

May 25, 2011
Globe All Wellness recalls lots of Slim Xtreme product

Globe All Wellness on Tuesday recalled all lots of its Slim Xtreme herbal slimming capsule upon learning that the Food and Drug Administration determined the product contains the undeclared drug ingredient sibutramine.

HOLLYWOOD, Fla. — Globe All Wellness on Tuesday recalled all lots of its Slim Xtreme herbal slimming capsule upon learning that the Food and Drug Administration determined the product contains the undeclared drug ingredient sibutramine.

Sibutramine was the active ingredient in the prescription weight-loss drug Meridia, which had been pulled off the U.S. market due to increased risk of cardiovascular events or stroke.

March 15, 2011
FDA attacks ‘lose pounds quick’ weight-loss frauds

The Food and Drug Administration on Tuesday outlined a new campaign attacking fraudulent weight-loss products marketed as dietary supplements, especially those companies that proffer a “magic pill” that almost immediately achieves weight loss.

SILVER SPRING, Md. — The Food and Drug Administration on Tuesday outlined a new campaign attacking fraudulent weight-loss products marketed as dietary supplements, especially those companies that proffer a “magic pill” that almost immediately achieves weight loss.

February 23, 2011
Amid counterfeit product warning, Biotab recalls two lots of Extenze

Biotab Nutraceuticals on Tuesday initiated a voluntary recall of two lots of Extenze nutritional supplement tablets.

MONROVIA, Calif. — Biotab Nutraceuticals on Tuesday initiated a voluntary recall of two lots of Extenze nutritional supplement tablets.

Some packages bearing lot numbers 0709241 and 0509075 are counterfeit products containing undeclared drug ingredients that can pose a serious risk to health, the company stated.

January 3, 2011
FDA announces recall of two adulterated drugs available online

The Food and Drug Administration last week prompted the recall of two more products sold as supplements but adulterated with prescription medicines.

SILVER SPRING, Md. — The Food and Drug Administration last week prompted the recall of two more products sold as supplements but adulterated with prescription medicines.

Drive Total Energy, headquartered in San Diego, recalled its Rock Hard Extreme and Passion Coffee dietary supplements. The FDA found that the products contained sulfoaildenafil, an analogue of sildenafil that is an FDA-approved drug used in the treatment of male erectile dysfunction.

December 8, 2010
FDA panel backs Contrave

A Food and Drug Administration advisory committee has recommended approval for an investigational diet pill.

SAN DIEGO — A Food and Drug Administration advisory committee has recommended approval for an investigational diet pill.

Orexigen Therapeutics and Takeda Pharmaceutical announced Tuesday that the FDA Endocrinologic and Metabolic Drugs Advisory Committee voted 13-7 that clinical trial data demonstrated that the benefits of the drug Contrave (naltrexone and bupropion) outweighed its risk and supported approval. The committee also voted 11-8 to recommend a study to examine Contrave’s effect on risk for cardiac disease.

December 7, 2010
Nonprofits urge for more means of addressing obesity epidemic

As a Food and Drug Administration advisory committee convenes to decide whether or not to approve a new drug for treating obesity, two nonprofit groups centered on the epidemic said more means of addressing it are needed.

SILVER SPRING, Md. — As a Food and Drug Administration advisory committee convenes to decide whether or not to approve a new drug for treating obesity, two nonprofit groups centered on the epidemic said more means of addressing it are needed.

October 7, 2010
Obesity drug withdrawn following trial showing heart attack, stroke risk

Clinical trial data indicating an increased risk of heart attack and stroke has led to...

SILVER SPRING, Md. Clinical trial data indicating an increased risk of heart attack and stroke has led to the removal from the market of an obesity drug made by Abbott, the Food and Drug Administration said Friday.

 

The FDA said the drug maker voluntarily withdrew the drug Meridia (sibutramine) following a required post-marketing trial showing that the drug increased by 16% the risk of nonfatal heart attacks and strokes, the need for resuscitation after the heart stopped and death.

 

 

July 8, 2010
FDA issues warning about Que She weight-loss supplement

The Food and Drug Administration on Thursday warned that Que She, marketed as an herbal...

March 9, 2010
Datamonitor projects diabetes drug market to reach $37 billion by 2018

The market for diabetes drugs will be worth $37 billion by 2018, up from $20...

January 17, 2010
FDA warns consumers about counterfeit Alli

The Food and Drug Administration on Monday issued a warning to consumers about a counterfeit...